Announcements Trials
Browse Landscape

Phase

Phase NA 25Phase 1/2 3Phase 2/3 1

Status

Recruiting 3Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Palliative Care × Clear all
NCT07510802 2026-04-06

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07486089 2026-03-20

DUAL-NK-BC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07467863 2026-03-12

DUO-NK-NSCLC

Beijing Biotech

Phase 1/2 Recruiting
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡